MedPath

Ultrasound RF Data for Discriminating Between Benign and Malignant Ovarian Masses

Not Applicable
Not yet recruiting
Conditions
Ovarian Cancer
Interventions
Diagnostic Test: RF data extraction
Registration Number
NCT06473766
Lead Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Brief Summary

Ultrasound imaging provides useful information for the characterization of ovarian masses as benign or malignant. The most accurate mathematical model to categorize ovarian masses is the IOTA ADNEX model.This model estimates the risk of malignancy and performs similarly to subjective assessment by an experienced ultrasound examiner for discriminating between benign and malignant adnexal masses. The ability of IOTA ADNEX to discriminate between benign and malignant masses is very good (area under the receiver operator characteristic curve 0.937 (95% CI: 0.915-0.954). The ADNEX model maintains its accuracy even in the hands of operators with different experience and training.

According to IOTA terminology, 13% of ovarian masses detected on ultrasound examination are classified as solid. Solid ovarian masses have a risk of malignancy of 60%-75%2 and the discrimination between benign and malignant in this morphological category is challenging. Additionally, it has been estimated that 30% (25/84; 95% CI 18 to 44%) of solid malignant ovarian masses are metastases from non-ovarian tumors. The discrimination between primary ovarian cancer and metastatic tumors in the ovary is also clinically important for planning adequate therapeutic procedures. It is worth exploring the predictive performance of the diagnostic tools in identifying ovarian masses with ultrasound solid morphology.

Preliminary data (unpublished) on radiomics analysis and ovarian masses provided that benign and malignant ovarian masses with solid morphology have different radiomics features in a monocentric retrospective study. However, no statistically significant differences have been observed between primary ovarian cancer and metastases to the ovary.

A new technology is emerging in engineering ultrasound field: the analysis of ultrasound summed RF data- raw data generated by the interface of ultrasound beams with human tissues. To date, raw data are not utilized for conventional imaging and their eventual role in clinical practice is unknown. Indeed, summed RF data could better correlate with biological parameters then parameters identifiable in B-mode images. Summed RF data could also improve radiomic analysis.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
Female
Target Recruitment
50
Inclusion Criteria
  1. Patients with a preoperative ultrasound diagnosis of a solid ovarian mass (solid according to IOTA terminology, i.e. 80% of the tumor consists of solid tissue).
  2. Patients who will undergo surgery within 120 days after the ultrasound examination.
  3. Patients at least 18 years old.
  4. Informed consent signed.
Exclusion Criteria
  1. Patients under 18 years of age.
  2. Patient refusal

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Feasibility of RF data to compare RF data in ovarian massesRF data extractionTo evaluate the feasibility of RF data in patients with ovarian masses with solid ultrasound morphology 1. To compare RF data in benign and malignant ovarian masses with ultrasound solid morphology. Histology will be the reference standard. 2. To compare RF data in primary invasive and metastases to the ovary. 3. To describe the reliability of RF data between different images of the same solid ovarian tumor.
Primary Outcome Measures
NameTimeMethod
number of examinations readable30 minutes

Feasibility measured as number of examinations readable, (i.e. number of patients with successful process with diagnosed solid ovarian masses, and acquisition of readable RF data)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

🇮🇹

Roma, Italy

© Copyright 2025. All Rights Reserved by MedPath